| Literature DB >> 12182866 |
Ruth Arnold1, David Beer, Gurdip Bhalay, Urs Baettig, Stephen P Collingwood, Sarah Craig, Nicholas Devereux, Andrew Dunstan, Angela Glen, Sylvie Gomez, Sandra Haberthuer, Trevor Howe, Stephen Jelfs, Heinz Moser, Reto Naef, Paul Nicklin, David Sandham, Rowan Stringer, Katharine Turner, Simon Watson, Mauro Zurini.
Abstract
In clinical studies, several inhibitors of phosphodiesterase 5 (PDE5) have demonstrated utility in the treatment of erectile dysfunction. We describe herein a series of 8-aryl xanthine derivatives which function as potent PDE5 inhibitors with, in many cases, high levels of selectivity versus other PDE isoforms.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12182866 DOI： 10.1016/s0960-894x(02)00480-8
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823